Pharmaceutical Technology

MAY 12, 2023

The division of infectious diseases at Weill Cornell Medicine carried out the work in collaboration with JAFRAL and JMI Laboratories. The team then engineered the phages through gene editing to improve their targeting ability.

Development 246

Development Bacteria Research Gene Editing 246

BioPharma Reporter

MARCH 2, 2021

The gene-editing and genome-engineering company, eGenesis, today announced the completion of a US$125m Series C financing round.

Gene Editing 52

Gene Editing Medicine Genome Genomics 52

Drug Discovery World

MAY 5, 2023

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. In contrast to DNA-based reprogramming and gene editing, the mRNA-based approach does not expose cells to expensive and potentially harmful viruses or DNA vectors.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

Drug Discovery World

JANUARY 9, 2023

The findings are published in Science Translational Medicine. . Using gene engineering, we are repurposing cancer cells to develop a therapeutic that kills tumour cells and stimulates the immune system to both destroy primary tumors and prevent cancer.” . CRISPR-Cas9 gene editing .

Scientist 52

Scientist Gene Editing Gene Engineer 52

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Drug Discovery World

MARCH 22, 2023

A new approach that delivers a ‘one-two punch’ to help T cells attack solid tumours is the focus of a preclinical study by researchers from the Perelman School of Medicine at the University of Pennsylvania. After CRISPR editing, the T cells were expanded and infused in solid tumour mice models.

Gene Editing 52

Gene Editing Gene Engineer Regulation 52

Drug Discovery World

JUNE 22, 2023

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights.

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

XTalks

JANUARY 26, 2024

Innovations in Cancer Therapy CRISPR/Cas9, a groundbreaking gene-editing technology, has demonstrated significant potential in oncology, offering new avenues for cancer treatment. CRISPR/Cas9 offers a pathway to potentially overcome this, by modifying genes that are responsible for drug resistance in cancer cells.

Research 118

Research Gene Editing Gene Genetics 118

Pharmaceutical Technology

JANUARY 10, 2023

Asklepios BioPharmaceutical has entered a research partnership and option agreement with ReCode Therapeutics for exploring its single-vector gene-editing platform. The new solution will enable complete gene insertion by delivering the gene-editing tool and DNA as mixed cargo to desired targets in one LNP.

Gene Editing 130

Gene Editing Gene Gene Therapy Genetics 130

Drug Discovery World

DECEMBER 12, 2022

The announcement followed the signing of deals to make new medicines available across the country. . Dr Ramakrishnan, who holds a Bachelor of Biotechnology and Biochemical Engineering from the University of Kerala in India, presented a proposal examining microbiome-based therapeutics for asthma. . Analysis .

Drugs 52

Drugs Gene Editing Genome Genomics 52

The Pharma Data

JANUARY 24, 2021

Bond joins Notch from Kite, where he most recently served as Vice President of Cellular Engineering. Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. ” Chris Bond , Ph.D., .

Engineer 52

Engineer Gene Editing Genome Genomics 52

Drug Discovery World

DECEMBER 20, 2022

Personalised and precision medicines will dominate pipelines. In its expected biotech trends for 2023, financial services company Nasdaq emphasises personalised medicine as a potential area for huge growth. . In summary, 2023 could be a very exciting year for life sciences.

Drugs 52

Drugs Gene Editing Clinical Trials Clinical Trials 52

Drug Discovery World

SEPTEMBER 6, 2022

By Dr. Deborah Phippard, Chief Scientific Officer of Precision for Medicine and Anshul Mangal, President & General Counsel of Project Farma. . In recent years the advanced therapy industry has been the most significant disruptor in medicine. ViaCyte, Beam, and Verve are all due to begin gene editing trials this year.

Gene Therapy 52

Gene Therapy Gene Gene Editing Manufacturing 52

Drug Discovery World

JANUARY 12, 2023

Scientists use complex gene editing and disease modeling systems to gain insights on the potential of CRISPR. . Most gene editing studies are performed in traditional 2D culture systems that model a simplified version of the tissue and biology in question. Limitations of organoids.

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

pharmaphorum

AUGUST 25, 2022

Explore approaches to boost safe gene-editing, approach regulatory affairs, turbocharge scale-up, optimize analytics and more to produce best-in-class therapies for immuno-oncology and regenerative medicine. Sana Biotechnology , Takeda and many more.

Gene Editing 40

Gene Editing Genome Genomics Engineer 40

Cloudbyz

MARCH 6, 2024

Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics. The rise of biologics represents a watershed moment in the history of medicine, ushering in a new era of precision, efficacy, and personalized care.

Gene 73

Gene Immune Response Manufacturing Gene Therapy 73

Bioengineer

JULY 19, 2021

Researchers at the Wake Forest Organoid Research Center (WFORCE), a joint venture between the Wake Forest Institute for Regenerative Medicine (WFIRM), and the Wake Forest Comprehensive Cancer Center, were the first to create appendiceal cancer organoids to use as a predictive model for potential treatment options (published 2018).

Engineer 52

Engineer Medicine Clinical Trials Clinical Trials 52

Bioengineer

JULY 23, 2021

Credit: Texas A&M Engineering. The team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station. Jain also has a joint appointment in the College of Medicine at Texas A&M. Jain also has a joint appointment in the College of Medicine at Texas A&M. ” ###.

Engineer 52

Engineer Gene Editing Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 1, 2021

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation.

Drugs 52

Drugs Engineer Drug Delivery Gene 52

XTalks

MARCH 28, 2024

Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment. For example, gene editing can possibly be used to correct cancer-causing mutations or enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

DECEMBER 15, 2022

Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukemia (AML). . Official comments .

Drugs 52

Drugs Genome Genomics Engineer 52

XTalks

JULY 14, 2022

A downstream approach has traditionally been used by scientists to map networks, wherein a gene for a protein is removed one at a time and the impact on the immune cell’s function is observed. CRISPR-Cas9 gene editing was used to simultaneously perturb thousands of genes by targeting specific points of genetic code.

Gene 98

Gene Regulation Protein Gene Editing 98

Drug Discovery World

MARCH 11, 2024

Researchers from Japan have used CRISPR gene editing to enhance the effectiveness of rejuvenated cytotoxic T lymphocytes (rejTs) for targeted immunotherapy. RejTs can be engineered to target HPV-specific antigens that are expressed predominantly in cervical cancer cells, constituting a type of targeted immunotherapy.

Gene Editing 52

Gene Editing Gene Engineer RNA 52

Delveinsight

FEBRUARY 25, 2021

Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site.

DNA 52

DNA In-Vivo Genetics Medicine 52

Delveinsight

AUGUST 27, 2020

The two drugs combined with radiation cleared the brain metastases in 75% of the animals, as reported in the journal Science Translational Medicine. Now, a research team that is led by scientists at Harvard University have used the CRISPR-Cas9 gene-editing technology to engineer human white fat so that it shows the properties of brown fat.

Vaccination 53

Vaccination Vaccine Research Trials 53

Delveinsight

SEPTEMBER 14, 2021

CEO of SR One, said that the ADARx team focuses on expeditiously translating their insights around RNA biology into novel medicines to benefit patients. Vor Biopharma has declared that the FDA has awarded their acute myeloid leukemia (AML) engineered hematopoietic stem cell therapy (eHSC), VOR33, a Fast Track Designation.

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

Drug Discovery World

NOVEMBER 24, 2023

However, as we see every day, modern medicine has both incremental and major improvements, showing that the best innovations and most transformative outcomes can come from extreme pressures. But ultimately, for medicines to be rolled out worldwide, they need to work with not against the market.

Research 59

Research Life Science Gene Editing Vaccination 59

The Pharma Data

NOVEMBER 22, 2021

State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem Sustainable environmental engineering aligned to Company’s zero carbon future. Over the once century, roughly 50 Nobel Prize winners in chemistry and physiology or drug have been associated with Cambridge.

Gene Editing 52

Gene Editing Engineer Production Scientist 52

Drug Discovery World

SEPTEMBER 6, 2022

The cell and gene therapy industry has experienced exponential growth in the last three years and as funding for the field continues to break records there are no signs of a slowdown. With 2,261 ongoing clinical trials in regenerative medicine, the FDA expects to approve 1 between 10 and 20 new cell and gene therapies a year by 2025.

Gene Therapy 52

Gene Therapy Gene Manufacturing Clinical Trials 52

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

Drug Discovery World

JUNE 7, 2023

That’s why at Macomics we have developed the ENIGMAC discovery platform, which allows stringent bioinformatic analysis coupled with macrophage gene editing technology; our platform enables strong target validation and drug screening using biologically relevant functional assays.

In-Vivo 52

In-Vivo Gene Editing Engineer Bioinformatics 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

STAT News

NOVEMBER 4, 2022

A man with muscular dystrophy who was first in line to receive an experimental gene editing therapy tailor made to treat the cause of his rare form of the disease has died. The clinical trial was to be the first time anyone got a gene editing therapy for muscular dystrophy.

Gene Editing 105

Gene Editing Gene Gene Therapy Clinical Trials 105

Drug Discovery World

APRIL 15, 2023

As the theme, Advancing the Frontiers of Cancer Science and Medicine , suggests, a number of announcements, results and presentations will take place at what is widely considered to be a flagship event for the cancer research community. Here are eight anticipated ‘curtain raisers’ in advance of the event: 1.

Antibody 52

Antibody Trials Research Gene Editing 52

Drug Discovery World

APRIL 14, 2023

Carl H June, MD, FAACR – Lifetime Achievement in Cancer Research June, a Fellow of the AACR Academy, is the Richard W Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies, and Director of the Parker Institute for Cancer Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania.

Genetics 52

Genetics Research Medicine Clinical Research 52

Drug Discovery World

APRIL 3, 2023

Optimer binders are engineered to overcome these problems. Beyond direct conjugation of therapeutic molecules for delivery, our aptamers can also be conjugated to larger vectors for use in precision medicines. These vectors could carry larger payloads to increase the precision of therapeutic mRNA or gene editing machinery for CRISPR.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52